Singapore markets close in 5 minutes

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
106.83-1.46 (-1.35%)
At close: 04:00PM EST
106.86 +0.03 (+0.03%)
After hours: 06:32PM EST
Full screen
Loading interactive chart…
  • Reuters

    Novo Nordisk says lower insulin prices in China dent 2022 outlook

    Novo Nordisk on Friday forecast its sales growth would slow by about 3% in 2022 because of lower prices and a drop in insulin sales volumes in China, denting the Danish diabetes drug maker's share price. The forecast comes after Novo received results from China's Volume Based Procurement (VBP) tender, which covers insulin sold at Chinese hospitals. "Novo Nordisk currently expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China," it said in a statement.

  • Motley Fool

    4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

    The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

  • Zacks

    Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion

    Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.